| Year |
Citation |
Score |
| 2022 |
Henry NL, Kim S, Hays RD, Diniz MA, Tighiouart M, Gresham G, Luu M, Cecchini RS, Yothers G, Rogatko A, Ganz PA. Toxicity Index, patient-reported outcomes, and persistence of breast cancer chemotherapy-associated side effects in NRG Oncology/NSABP B-30. Npj Breast Cancer. 8: 123. PMID 36402796 DOI: 10.1038/s41523-022-00489-9 |
0.474 |
|
| 2021 |
Henry NL, Kim S, Hays RD, Diniz MA, Luu M, Cecchini RS, Yothers G, Rogatko A, Ganz PA. Toxicity Index, Patient-Reported Outcomes, and Early Discontinuation of Endocrine Therapy for Breast Cancer Risk Reduction in NRG Oncology/NSABP B-35. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2100910. PMID 34554865 DOI: 10.1200/JCO.21.00910 |
0.488 |
|
| 2021 |
Ganz PA, Cecchini RS, Fehrenbacher L, Geyer CE, Rastogi P, Crown JP, Thirlwell MP, Ellison DM, Boileau JF, Flynn PJ, Jeong JH, Mamounas EP, Wolmark N. NRG Oncology/NSABP B-47 menstrual history study: impact of adjuvant chemotherapy with and without trastuzumab. Npj Breast Cancer. 7: 55. PMID 34016989 DOI: 10.1038/s41523-021-00264-2 |
0.397 |
|
| 2020 |
Basik M, Cecchini RS, Santos JFDL, Umphrey HR, Julian TB, Mamounas EP, White J, Lucas PC, Balanoff C, Tan AR, Weber JJ, Edmonson DA, Brown-Glaberman UA, Diego EJ, Teshome M, et al. Abstract GS5-05: Primary analysis of NRG-BR005, a phase II trial assessing accuracy of tumor bed biopsies in predicting pathologic complete response (pCR) in patients with clinical/radiological complete response after neoadjuvant chemotherapy (NCT) to explore the feasibility of breast-conserving treatment without surgery Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-Gs5-05 |
0.445 |
|
| 2019 |
Fehrenbacher L, Cecchini RS, Geyer CE, Rastogi P, Costantino JP, Atkins JN, Crown JP, Polikoff J, Boileau JF, Provencher L, Stokoe C, Moore TD, Robidoux A, Flynn PJ, Borges VF, et al. NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1901455. PMID 31821109 DOI: 10.1200/Jco.19.01455 |
0.622 |
|
| 2019 |
Vicini FA, Cecchini RS, White JR, Arthur DW, Julian TB, Rabinovitch RA, Kuske RR, Ganz PA, Parda DS, Scheier MF, Winter KA, Paik S, Kuerer HM, Vallow LA, Pierce LJ, et al. Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial. Lancet (London, England). PMID 31813636 DOI: 10.1016/S0140-6736(19)32514-0 |
0.583 |
|
| 2019 |
de Azambuja E, Ponde N, Procter M, Rastogi P, Cecchini RS, Lambertini M, Ballman K, Aspitia AM, Zardavas D, Roca L, Gelber RD, Piccart-Gebhart M, Suter T. A pooled analysis of the cardiac events in the trastuzumab adjuvant trials. Breast Cancer Research and Treatment. PMID 31605311 DOI: 10.1007/S10549-019-05453-Z |
0.562 |
|
| 2019 |
Ganz PA, Cecchini RS, White JR, Vicini F, Julian TB, Arthur DW, Rabinovitch R, Kuske RR, Parda DS, Scheier M, Winter KA, Paik S, Kuerer HM, Vallow L, Pierce LJ, et al. Patient-reported outcomes (PROs) in NRG oncology/NSABP B-39/RTOG 0413: A randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) in stage 0, I, or II breast cancer. Journal of Clinical Oncology. 37: 508-508. DOI: 10.1200/Jco.2019.37.15_Suppl.508 |
0.48 |
|
| 2019 |
Vicini F, Cecchini R, White J, Julian T, Arthur D, Rabinovitch R, Kuske R, Parda D, Ganz P, Scheier M, Winter K, Paik S, Kuerer H, Vallow L, Pierce L, et al. Abstract GS4-04: Primary results of NSABP B-39/RTOG 0413 (NRG Oncology): A randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) for women with stage 0, I, or II breast cancer Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-Gs4-04 |
0.583 |
|
| 2019 |
Pogue-Geile KL, Wang Y, Feng H, Lipchik C, Kim RS, Cecchini RS, Jacobs SA, Srinivasan A, Costantino JP, Mamounas EP, Geyer CE, Rastogi P, Lucas PC, Paik S, Osborne CK, et al. Abstract 4064: Association of molecular signatures, mutations, and sTILs, with pCR in breast cancer patients in NRG Oncology/NSABP B-52 Cancer Research. 79: 4064-4064. DOI: 10.1158/1538-7445.Am2019-4064 |
0.42 |
|
| 2018 |
Cook ED, Yeager KA, Cecchini RS, Boparai J, Brown CL, Duncan M, Cronin WM, Paskett ED. Recruitment practices for U.S. minority and underserved populations in NRG oncology: Results of an online survey. Contemporary Clinical Trials Communications. 10: 100-104. PMID 30023443 DOI: 10.1016/J.Conctc.2018.03.003 |
0.343 |
|
| 2018 |
De Azambuja E, Ponde NF, Procter MJ, Rastogi P, Cecchini RS, Ballman KV, Moreno-Aspitia A, Zardavas D, Roca L, Gelber RD, Piccart M, Suter TM. Meta-analysis of the cardiac events in the adjuvant trastuzumab trials. Journal of Clinical Oncology. 36: 10066-10066. DOI: 10.1200/Jco.2018.36.15_Suppl.10066 |
0.345 |
|
| 2018 |
Fehrenbacher L, Cecchini R, Geyer C, Rastogi P, Costantino J, Atkins J, Polikoff J, Boileau J, Provencher L, Stokoe C, Moore T, Robidoux A, Borges V, Albain K, Swain S, et al. Abstract GS1-02: NSABP B-47 (NRG oncology): Phase III randomized trial comparing adjuvant chemotherapy with adriamycin (A) and cyclophosphamide (C) → weekly paclitaxel (WP), or docetaxel (T) and C with or without a year of trastuzumab (H) in women with node-positive or high-risk node-negative invasive breast cancer (IBC) expressing HER2 staining intensity of IHC 1+ or 2+ with negative FISH (HER2-Low IBC) Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-Gs1-02 |
0.441 |
|
| 2017 |
Ganz PA, Romond EH, Cecchini RS, Rastogi P, Geyer CE, Swain SM, Jeong JH, Fehrenbacher L, Gross HM, Brufsky AM, Flynn PJ, Wahl TA, Seay TE, Wade JL, Biggs DD, et al. Long-Term Follow-Up of Cardiac Function and Quality of Life for Patients in NSABP Protocol B-31/NRG Oncology: A Randomized Trial Comparing the Safety and Efficacy of Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel With AC Followed by Paclitaxel and Trastuzumab in Patients With Node-Positive Breast Cancer With Tumors Overexpressing Human Epidermal Growth Factor Receptor 2. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017741165. PMID 29072977 DOI: 10.1200/Jco.2017.74.1165 |
0.451 |
|
| 2017 |
Yeager K, Cronin WM, Cecchini RS, Duncan M, Boparai J, Cook ED, Brown CL, Paskett ED. Abstract A76: Recruitment practices for minority and underserved populations in NRG Oncology: Results of an online survey Cancer Epidemiology, Biomarkers & Prevention. 26. DOI: 10.1158/1538-7755.Disp16-A76 |
0.325 |
|
| 2017 |
Rimawi M, Cecchini R, Rastogi P, Geyer C, Fehrenbacher L, Stella P, Dayao Z, Rabinovitch R, Dyar S, Flynn P, Baez-Diaz L, Paik S, Swain S, Mamounas E, Osborne C, et al. Abstract S3-06: A phase III trial evaluating pCR in patients with HR+, HER2-positive breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP) +/- estrogen deprivation: NRG Oncology/NSABP B-52 Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-S3-06 |
0.603 |
|
| 2016 |
Ganz P, Cecchini R, Julian T, Margolese R, Costantino J, Vallow L, Albain K, Whitworth P, Cianfrocca M, Brufsky A, Gross H, Soori G, Hopkins J, Fehrenbacher L, Sturtz K, et al. Abstract S6-04: Patient-reported outcome (PRO) results, NRG Oncology/NSABP B-35: A clinical trial of anastrozole (A) vs tamoxifen (tam) in postmenopausal patients with DCIS undergoing lumpectomy plus radiotherapy Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-S6-04 |
0.536 |
|
| 2015 |
Cecchini RS, Julian TB, Ganz PA, Costantino JP, Vallow L, Albain KS, Whitworth PW, Cianfrocca ME, Brufsky A, Gross HM, Soori GS, Hopkins JO, Fehrenbacher L, Sturtz K, Wozniak TF, et al. Primary results, NRG Oncology/NSABP B-35: A clinical trial of anastrozole (A) versus tamoxifen (tam) in postmenopausal patients with DCIS undergoing lumpectomy plus radiotherapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: LBA500. PMID 28147716 DOI: 10.1200/Jco.2015.33.18_Suppl.Lba500 |
0.583 |
|
| 2015 |
Ganz PA, Cecchini RS, Julian TB, Margolese RG, Costantino JP, Vallow LA, Albain KS, Whitworth PW, Cianfrocca ME, Brufsky AM, Gross HM, Soori GS, Hopkins JO, Fehrenbacher L, Sturtz K, et al. Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. Lancet (London, England). PMID 26686960 DOI: 10.1016/S0140-6736(15)01169-1 |
0.517 |
|
| 2015 |
Margolese RG, Cecchini RS, Julian TB, Ganz PA, Costantino JP, Vallow LA, Albain KS, Whitworth PW, Cianfrocca ME, Brufsky AM, Gross HM, Soori GS, Hopkins JO, Fehrenbacher L, Sturtz K, et al. Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. Lancet (London, England). PMID 26686957 DOI: 10.1016/S0140-6736(15)01168-X |
0.398 |
|
| 2015 |
Cecchini R, Swain SM, Costantino JP, Rastogi P, Jeong JH, Anderson SJ, Tang G, Geyer CE, Lembersky BC, Romond EH, Paterson AH, Wolmark N. Body mass index at diagnosis and breast cancer survival prognosis in clinical trial populations from NRG Oncology/NSABP B-30, B-31, B-34, and B-38. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. PMID 26545405 DOI: 10.1158/1055-9965.Epi-15-0334-T |
0.553 |
|
| 2015 |
Wickerham DL, Cecchini RS, Vogel VG, Costantino JP, Cronin WM, Bevers TB, Fehrenbacher L, Pajon ER, Wade JL, Robidoux A, Margolese RG, James JM, Runowicz CD, Ganz PA, Reis SE, et al. Final updated results of the NRG Oncology/NSABP Protocol P-2: Study of Tamoxifen and Raloxifene (STAR) in preventing breast cancer. Journal of Clinical Oncology. 33: 1500-1500. DOI: 10.1200/Jco.2015.33.15_Suppl.1500 |
0.611 |
|
| 2013 |
Cecchini R, Swain S, Costantino J, Rastogi P, Jeong J, Anderson S, Tang G, Geyer C, Lembersky B, Romond E, Paterson A, Wolmark N. Abstract PD2-1: Body mass index at diagnosis and breast cancer survival prognosis among clinical trial populations: Results from NSABP B-30, B-31, B-34, and B-38 Cancer Research. 73. DOI: 10.1158/0008-5472.Sabcs13-Pd2-1 |
0.596 |
|
| 2012 |
Cecchini RS, Costantino JP, Cauley JA, Cronin WM, Wickerham DL, Bandos H, Weissfeld JL, Wolmark N. Baseline mammographic breast density and the risk of invasive breast cancer in postmenopausal women participating in the NSABP study of tamoxifen and raloxifene (STAR). Cancer Prevention Research (Philadelphia, Pa.). 5: 1321-9. PMID 23060039 DOI: 10.1158/1940-6207.Capr-12-0273 |
0.644 |
|
| 2012 |
Kidwell KM, Yothers G, Ganz PA, Land SR, Ko CY, Cecchini RS, Kopec JA, Wolmark N. Long-term neurotoxicity effects of oxaliplatin added to fluorouracil and leucovorin as adjuvant therapy for colon cancer: results from National Surgical Adjuvant Breast and Bowel Project trials C-07 and LTS-01. Cancer. 118: 5614-22. PMID 22569841 DOI: 10.1002/Cncr.27593 |
0.492 |
|
| 2012 |
Amir E, Cecchini RS, Ganz PA, Costantino JP, Beddows S, Hood N, Goodwin PJ. 25-Hydroxy vitamin-D, obesity, and associated variables as predictors of breast cancer risk and tamoxifen benefit in NSABP-P1. Breast Cancer Research and Treatment. 133: 1077-88. PMID 22415479 DOI: 10.1007/S10549-012-2012-X |
0.565 |
|
| 2012 |
Cecchini RS, Costantino JP, Cauley JA, Cronin WM, Wickerham DL, Land SR, Weissfeld JL, Wolmark N. Body mass index and the risk for developing invasive breast cancer among high-risk women in NSABP P-1 and STAR breast cancer prevention trials. Cancer Prevention Research (Philadelphia, Pa.). 5: 583-92. PMID 22318751 DOI: 10.1158/1940-6207.Capr-11-0482 |
0.655 |
|
| 2012 |
Amir E, Cecchini RS, Ganz PA, Costantino JP, Beddows S, Hood N, Goodwin PJ. Erratum to: 25-Hydroxy vitamin-D, obesity, and associated variables as predictors of breast cancer risk and tamoxifen benefit in NSABP-P1 Breast Cancer Research and Treatment. 135: 923-923. DOI: 10.1007/s10549-012-2178-2 |
0.394 |
|
| 2011 |
Runowicz CD, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Ford LG, Vogel VG, Wolmark N. Gynecologic conditions in participants in the NSABP breast cancer prevention study of tamoxifen and raloxifene (STAR). American Journal of Obstetrics and Gynecology. 205: 535.e1-5. PMID 21872200 DOI: 10.1016/J.Ajog.2011.06.067 |
0.588 |
|
| 2011 |
Ganz PA, Land SR, Geyer CE, Cecchini RS, Costantino JP, Pajon ER, Fehrenbacher L, Atkins JN, Polikoff JA, Vogel VG, Erban JK, Livingston RB, Perez EA, Mamounas EP, Wolmark N, et al. Menstrual history and quality-of-life outcomes in women with node-positive breast cancer treated with adjuvant therapy on the NSABP B-30 trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 1110-6. PMID 21300930 DOI: 10.1200/Jco.2010.29.7689 |
0.593 |
|
| 2011 |
Amir E, Cecchini RS, Ganz PA, Costantino JP, Beddows S, Hood N, Goodwin PJ. 25-hydroxy vitamin D (VitD) and associated variables as predictors of breast cancer (BC) risk and tamoxifen benefit in NSABP-P1. Journal of Clinical Oncology. 29: 1528-1528. DOI: 10.1200/Jco.2011.29.15_Suppl.1528 |
0.417 |
|
| 2011 |
Julian T, Costantino J, Vicini F, White J, Cecchini R, Winter K, Arthur D, Kuske R, Rabinovitch R, Parda D, Mamounas E, Curran W, Wolmark N. OT2-06-02: A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) vs Partial Breast Irradiation (PBI) for Women with Stage 0, 1, or 2 Breast Cancer: NSABP B-39/RTOG 0413. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-Ot2-06-02 |
0.567 |
|
| 2010 |
Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER, Wade JL, Robidoux A, Margolese RG, James J, Runowicz CD, Ganz PA, et al. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer. Cancer Prevention Research (Philadelphia, Pa.). 3: 696-706. PMID 20404000 DOI: 10.1158/1940-6207.Capr-10-0076 |
0.612 |
|
| 2009 |
Wickerham DL, Costantino JP, Vogel VG, Cronin WM, Cecchini RS, Ford LG, Wolmark N. The use of tamoxifen and raloxifene for the prevention of breast cancer. Recent Results in Cancer Research. Fortschritte Der Krebsforschung. ProgrèS Dans Les Recherches Sur Le Cancer. 181: 113-9. PMID 19213563 DOI: 10.1007/978-3-540-69297-3_12 |
0.605 |
|
| 2009 |
Swain SM, Land SR, Ritter MW, Costantino JP, Cecchini RS, Mamounas EP, Wolmark N, Ganz PA. Amenorrhea in premenopausal women on the doxorubicin-and-cyclophosphamide-followed-by-docetaxel arm of NSABP B-30 trial. Breast Cancer Research and Treatment. 113: 315-20. PMID 18302020 DOI: 10.1007/S10549-008-9937-0 |
0.49 |
|
| 2008 |
Cronin WM, Cecchini RS, Wickerham DL, Vogel VG, Costantino JP, Wolmark N. Factors associated with participant adherence in the NSABP Study of Tamoxifen and Raloxifene (STAR) Journal of Clinical Oncology. 26: 6518-6518. DOI: 10.1200/Jco.2008.26.15_Suppl.6518 |
0.46 |
|
| 2007 |
Deutsch M, Land SR, Begovic M, Cecchini R, Wolmark N. An association between postoperative radiotherapy for primary breast cancer in 11 National Surgical Adjuvant Breast and Bowel Project (NSABP) studies and the subsequent appearance of pleural mesothelioma. American Journal of Clinical Oncology. 30: 294-6. PMID 17551308 DOI: 10.1097/01.Coc.0000256102.40842.78 |
0.617 |
|
| 2007 |
Land SR, Kopec JA, Cecchini RS, Ganz PA, Wieand HS, Colangelo LH, Murphy K, Kuebler JP, Seay TE, Needles BM, Bearden JD, Colman LK, Lanier KS, Pajon ER, Cella D, et al. Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 25: 2205-11. PMID 17470850 DOI: 10.1200/Jco.2006.08.6652 |
0.373 |
|
| 2007 |
Kopec JA, Yothers G, Ganz PA, Land SR, Cecchini RS, Wieand HS, Lembersky BC, Wolmark N. Quality of life in operable colon cancer patients receiving oral compared with intravenous chemotherapy: results from National Surgical Adjuvant Breast and Bowel Project Trial C-06. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 25: 424-30. PMID 17264338 DOI: 10.1200/Jco.2005.05.2597 |
0.452 |
|
| 2006 |
Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER, Wade JL, Robidoux A, Margolese RG, James J, Lippman SM, Runowicz CD, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. Jama. 295: 2727-41. PMID 16754727 DOI: 10.1097/01.Ogx.0000238648.23538.42 |
0.619 |
|
| 2006 |
Wickerham DL, Costantino JP, Vogel V, Cronin W, Cecchini R, Atkins J, Bevers T, Fehrenbacher L, McCaskill-Stevens W, Wolmark N. The study of tamoxifen and raloxifene (STAR): Initial findings from the NSABP P-2 breast cancer prevention study Journal of Clinical Oncology. 24: LBA5-LBA5. DOI: 10.1200/Jco.2006.24.18_Suppl.Lba5 |
0.618 |
|
| 2006 |
Land SR, Kopec J, Cecchini R, Ganz PA, Wieand H, Colangelo L, Sharif S, Kuebler JP, Costantino J, Wolmark N. Patient-reported neurotoxicity with FULV versus FLOX in patients with stage II or III carcinoma of the colon: Results of NSABP Protocol C-07 Journal of Clinical Oncology. 24: 3564-3564. DOI: 10.1200/Jco.2006.24.18_Suppl.3564 |
0.352 |
|
| 2005 |
Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, Bevers TB, Kavanah MT, Atkins JN, Margolese RG, Runowicz CD, James JM, Ford LG, Wolmark N. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. Journal of the National Cancer Institute. 97: 1652-62. PMID 16288118 DOI: 10.1093/Jnci/Dji372 |
0.623 |
|
| Show low-probability matches. |